MRSA Coverage Antibiotic Regimen
Add vancomycin 15-20 mg/kg IV every 8-12 hours, linezolid 600 mg PO/IV twice daily, or daptomycin 4-6 mg/kg IV daily to your standard therapy, with the specific choice depending on infection type and severity. 1
Outpatient MRSA Coverage
For outpatient skin and soft tissue infections requiring MRSA coverage, the following oral options are available:
Monotherapy Options (covers MRSA only):
- Clindamycin 300-450 mg PO three times daily (first-line for purulent cellulitis) 1
- TMP-SMX 1-2 double-strength tablets PO twice daily 1
- Doxycycline 100 mg PO twice daily or minocycline 200 mg once, then 100 mg PO twice daily 1
- Linezolid 600 mg PO twice daily (more expensive alternative) 1
Dual Coverage (MRSA + β-hemolytic streptococci):
When coverage for both MRSA and streptococci is needed:
- Clindamycin alone (covers both organisms) 1
- TMP-SMX or tetracycline PLUS amoxicillin 500 mg PO three times daily 1
- Linezolid alone (covers both organisms) 1
Duration: 5-10 days for outpatient SSTI 1
Inpatient/Complicated Infections
For hospitalized patients with complicated skin and soft tissue infections, bacteremia, or pneumonia:
First-Line IV Options:
- Vancomycin 15-20 mg/kg IV every 8-12 hours (traditional first-line) 1
- Linezolid 600 mg IV/PO twice daily (equivalent efficacy, particularly for pneumonia) 1, 2
- Daptomycin 4 mg/kg IV daily for SSTI or 6 mg/kg IV daily for bacteremia/endocarditis 1, 3
- Telavancin 10 mg/kg IV daily 1
- Clindamycin 600 mg IV/PO three times daily (if local resistance <10%) 1
Duration: 7-14 days for complicated SSTI, individualized for bacteremia/endocarditis 1
Special Considerations by Infection Type
For MRSA Bacteremia:
- Initial empiric therapy: vancomycin or daptomycin 3
- Daptomycin 6 mg/kg IV daily is non-inferior to vancomycin (treatment success 44% vs 42%) 3
- For persistent bacteremia (≥48 hours): Consider high-dose daptomycin (8-10 mg/kg) with β-lactam combination or ceftaroline 4, 5
- Mortality risk with prolonged bacteremia: 39% at 90 days 3
For MRSA Pneumonia:
- Linezolid may be superior to vancomycin (clinical success rate 55% higher with linezolid) 2
- Alternative: vancomycin plus rifampin combination 2
For Complicated SSTI:
- Linezolid shows superior clinical success rates compared to vancomycin (RR 1.71,95% CI 1.45-2.02) 2
- Tedizolid may be optimal for cSSTI 2
- Minocycline plus rifampin combination shows highest efficacy (RR 2.77,95% CI 1.06-7.21) 2
Pediatric Dosing Adjustments
- Vancomycin: 15 mg/kg IV every 6 hours 1
- Clindamycin: 10-13 mg/kg/dose IV/PO every 6-8 hours (max 40 mg/kg/day) 1
- Linezolid: 10 mg/kg/dose PO/IV every 8 hours for children <12 years (max 600 mg/dose); 600 mg twice daily for children ≥12 years 1
- TMP-SMX: 4-6 mg/kg trimethoprim component every 12 hours 1
- Avoid tetracyclines in children <8 years of age 1
Critical Pitfalls to Avoid
- Do NOT use rifampin as monotherapy or adjunctive therapy for SSTI (increases resistance without benefit) 1
- TMP-SMX is pregnancy category C/D: contraindicated in third trimester and infants <2 months 1
- Clindamycin carries higher risk of C. difficile infection compared to other oral agents 1
- For nonpurulent cellulitis without systemic toxicity: Start with β-lactam (e.g., cefazolin), add MRSA coverage only if no clinical response 1
- Source control is mandatory: Remove infected devices, drain abscesses, perform surgical debridement as indicated 3
Emerging Evidence
Recent network meta-analysis suggests linezolid may be the preferred agent for MRSA infections overall despite higher adverse effect rates, with improved clinical and microbiological success rates compared to vancomycin 2. However, vancomycin and daptomycin remain guideline-recommended first-line agents based on extensive clinical experience 1, 3.